Canada markets open in 56 minutes

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4800-0.0200 (-0.80%)
At close: 4:00PM EDT
2.4800 0.00 (0.00%)
Pre-Market: 07:43AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

    Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present Opportunities for Future Partnerships BOSTON and LONDON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today will present on the company’s discovery and research efforts in hematopoietic stem cell (HSC) gene therapy, including an update on the OTL-104

  • GlobeNewswire

    Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

    Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today an

  • GlobeNewswire

    Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021

    BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor Event on Tuesday, September 14, 2021, from 7:00 a.m. to 8:00 a.m. ET. Members of Orchard’s management team will present updates from the company’s research and discovery efforts in hematopoietic stem cell (HSC) gene therapy, specifically the OTL-104 program for NOD2 Crohn's disease, and highlight the potentia